CytomX Therapeutics, Inc. (CTMX)

Price$3.45

Value ScoreD

Growth ScoreF

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-20.44%

Price vs S&P 500 (4W)-18.85%

VGM Score26.09

Market Capitalization$755.43M

P/E Ratio (Annual)23.50x

All Metrics

Book Value / Share (Quarterly)$1.47

P/TBV (Annual)7.32x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)12.72%

Cash Flow / Share (Quarterly)$-0.37

Price vs S&P 500 (YTD)-26.43%

Net Profit Margin (TTM)-166.40%

EPS (TTM)$-0.35

10-Day Avg Trading Volume3.21M

EPS Excl Extra (TTM)$-0.35

Revenue Growth (5Y)-5.37%

EPS (Annual)$-0.13

ROI (Annual)-17.54%

Net Profit Margin (5Y Avg)-99.53%

Cash / Share (Quarterly)$1.59

P/E Basic Excl Extra (TTM)26.73x

Revenue Growth QoQ (YoY)-79.85%

P/E Normalized (Annual)23.50x

ROA (Last FY)-11.46%

Revenue Growth TTM (YoY)-75.91%

EBITD / Share (TTM)$-0.40

ROE (5Y Avg)-81.98%

Operating Margin (TTM)-181.92%

Cash Flow / Share (Annual)$-0.45

P/B Ratio2.36x

P/B Ratio (Quarterly)3.18x

Net Income / Employee (Annual)$-251,700

EV / Revenue (TTM)20.44x

Net Interest Coverage (TTM)-87.50x

ROA (TTM)-28.02%

EV / EBITDA (TTM)29.80x

EPS Incl Extra (Annual)$-0.13

Current Ratio (Annual)3.09x

Quick Ratio (Quarterly)10.21x

3-Month Avg Trading Volume5.68M

52-Week Price Return42.86%

P/E Incl Extra (TTM)26.73x

Revenue / Employee (TTM)$515,100

Tangible BV / Share (Quarterly)$1.47

P/S Ratio (Annual)9.91x

Asset Turnover (Annual)0.50x

52-Week High$8.21

Operating Margin (5Y Avg)-103.81%

EPS Excl Extra (Annual)$-0.13

CapEx CAGR (5Y)-37.46%

Tangible BV CAGR (5Y)5.15%

26-Week Price Return-4.51%

Quick Ratio (Annual)2.98x

13-Week Price Return-34.31%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)10.38x

Enterprise Value$726.60M

Revenue / Share Growth (5Y)-23.99%

Asset Turnover (TTM)0.17x

Book Value / Share Growth (5Y)-23.01%

Revenue / Employee (Annual)$1,104,400

Pretax Margin (Annual)-22.48%

Cash / Share (Annual)$0.81

3-Month Return Std Dev117.06%

Net Income / Employee (TTM)$-857,100

ROE (Last FY)-17.54%

Net Interest Coverage (Annual)-47.58x

EPS Basic Excl Extra (Annual)$-0.13

P/FCF (TTM)81.23x

Receivables Turnover (TTM)27.32x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.35

Receivables Turnover (Annual)29.79x

ROI (TTM)-36.61%

P/S Ratio (TTM)21.25x

Pretax Margin (5Y Avg)-98.67%

Revenue / Share (Annual)$0.55

Tangible BV / Share (Annual)$0.58

Price vs S&P 500 (52W)14.65%

P/E Ratio (TTM)26.73x

EPS Growth TTM (YoY)-93.03%

Year-to-Date Return-15.49%

5-Day Price Return-4.26%

EPS Normalized (Annual)$-0.13

ROA (5Y Avg)-11.50%

Net Profit Margin (Annual)-22.79%

Month-to-Date Return-14.69%

Cash Flow / Share (TTM)$-0.39

EBITD / Share (Annual)$-0.15

Operating Margin (Annual)-29.35%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-81.98%

P/E Excl Extra (TTM)26.73x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.35

P/TBV (Quarterly)3.18x

P/B Ratio (Annual)7.29x

Pretax Margin (TTM)-165.74%

Book Value / Share (Annual)$0.58

Price vs S&P 500 (13W)-44.05%

Beta2.12x

P/FCF (Annual)251.81x

Revenue / Share (TTM)$0.20

ROE (TTM)-36.61%

52-Week Low$1.72

vGradeD

gGradeF

mGradeD

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.10est. -0.12

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.27

4.33

4.40

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
CTMXCytomX Therapeutics, Inc.	D	F	D	$3.45
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
ABTAbbott Laboratories	C	C	D	$87.78
PFEPfizer Inc.	B	C	C	$25.63
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

CytomX Therapeutics is a clinical-stage oncology company developing probody therapeutics—masked, conditionally activated biologics designed to target the tumor microenvironment. The company's proprietary technology platform creates cancer immunotherapies that activate specifically in tumors while remaining inactive in healthy tissues, enhancing efficacy and reducing potential side effects.